

CMFRI Commercializes Seaweed-Based Nutraceuticals

The <u>Indian Council of Agricultural Research(ICAR)</u>- Central Marine Fisheries Research Institute (CMFRI) has successfully commercialized two <u>seaweed-based</u> nutraceutical products, CadalminTM Immunalgin extract (CadalminTM IMe) and CadalminTM Antihypercholesterolemic extract (CadalminTM ACe).

- These products, developed with eco-friendly 'green' technology, aim to boost <u>anti-viral</u> **immunity** and combat high cholesterol or dyslipidemia (imbalance of cholesterol).
- The product is positioned as a potential remedy against <u>post-Covid complications</u>, exhibiting antiviral properties against the delta variant of <u>SARS CoV-2</u>.
- Seaweeds, primitive marine algae, lacking roots, stems, and leaves, play a vital role in marine ecosystems.
 - Seaweeds offer nutritional benefits and medicinal properties, containing anti-inflammatory and anti-microbial agents with potential cancer-fighting effects.

Read more...

PDF Reference URL: https://www.drishtiias.com/printpdf/cmfri-commercializes-seaweed-based-nutraceuticals